# mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC

> **NCT04895137** · PHASE2 · COMPLETED · sponsor: **Sixth Affiliated Hospital, Sun Yat-sen University** · enrollment: 42 (actual)

## Conditions studied

- Colorectal Cancer
- Immunotherapy

## Interventions

- **DRUG:** mFOLFOX6+Bevacizumab+PD-1 monoclonal antibody treatment combinations

## Key facts

- **NCT ID:** NCT04895137
- **Lead sponsor:** Sixth Affiliated Hospital, Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-01
- **Primary completion:** 2024-09-30
- **Final completion:** 2024-09-30
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2025-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04895137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04895137, "mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04895137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*